We proudly honor the following individuals who were presented with Division of Hematology awards in 2018.
9 News. A new treatment (Venetoclax + Azacitidine) appears to be more aggressive than the cancer it treats.
9 News. For the second year in a row, UCHealth is doing their "Hit the Mitt" campaign - if a player hits a banner in the stands of Coors Field with a home run, UCHealth donates $5,000 to a leukemia and lymphoma society.
Colorado Public Radio covers a CU trial drug, venetoclax, which is producing a 91 percent response rate in Acute Myeloid Leukemia (AML).
Chemotherapy and bone marrow transplant are the standard-of-care for AML. Now the basic science from Jordan’s lab and the results from clinical trials in Pollyea’s and Smith’s patients are leading to a new paradigm for the treatment of AML.
Cancer Center announces two newly endowed chairs: Daniel Pollyea, MD, recipient of the Robert H. Allen Endowed Chair in Hematology Research, and Eric Pietras, PhD, recipient of the Ceo Meador/George Ryland Scott Endowed Chair in Hematology Research.
Clinical trial results published in the journal Nature Medicine show 91 percent response rate to the combination of venetoclax with azacitidine in older adults newly diagnosed with acute myeloid leukemia (AML).
Cancer gets energy in the form of glucose. But how does it get this glucose? A recent study shows that leukemia undercuts the ability of normal cells to consume glucose, leaving more glucose available to feed its own growth.
Angelo D’Alessandro, PhD, will be honored by receiving the title of National Blood Foundation Scholar next month for completing a study funded by an NBF early-career Scientific Research Grant in 2016.
Nathan Kissack figured he pulled a muscle while cutting hay for the cows on his ranch. Worried about his back, Kissack went to see a buddy who’s a chiropractor. The news was bad. An X-ray showed a large tumor right in the middle of Kissack’s chest.
The multidisciplinary clinic targets cutaneous lymphoma, a difficult-to-diagnose cancer that attacks white blood cells and arises in the skin.
In one of the most exciting developments in the fight against cancer, CAR-T immunotherapy delivers a remarkable respite from blood cancer.
LINDSEY LYLE, MS, PA-C, and ALEX HIROSE, MMS, PA-C publish
Iron Overload in Myelodysplastic Syndromes: Pathophysiology, Consequences, Diagnosis, and Treatment
Nurse practitioners (NP) and physician assistants (PA) are an integral part of the BDC healthcare team caring for patients in the hospital, clinics and procedural settings.
Dwight C. Macero, MS, PA-C, discusses the role that advanced practice providers play in managing the side effects of hematologic treatments.